Close this search box.
Subscriber Log In

Five Reasons You Can’t Ignore Payers During Pipeline Development


Could previously launched drugs that significantly missed sales expectations have met a different fate if their manufacturers had accounted for payer perspectives in their early-stage development strategy?   Let’s start with some stats. About half of the drugs launched in the last 15 years underperformed analysts’ sales estimates by more than 20%1. Only one-fifth of […]